Subjects in replicate BE study EU/FDA [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2015-03-02 12:38 (3336 d 17:48 ago) – Posting: # 14521
Views: 27,065

Dear Relaxation.

❝ As a quick example (method A on the EMA dataset I (?, the 4 period one))

❝ Original result:

❝ 115.66 (107.11-124.97)

❝ Incomplete subjects excluded by hand:

❝ 115.46 (106.49-125.19)

❝ [no 11/20/24/31/42/67/69/71] --> no automatic excludion of incomplete data sets


All the subjects with incomplete data in the EMA dataset I have at least one period with T and one with R. Thus they of course have a contribution to the evaluation of T-R and you will find differences if including or excluding them.

❝ For the show, subject 100 with R twice with values of 1000 and 500 added:

❝ 112.21 (1.16-10833.43)

❝ --> even subjects without data for a T vs R comparison have an impact (choosing such values for ln(data) was a little bit too much but is nicely illustrating, isn't it).


Seems here you are totally correct :thumb up:.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,654 registered users;
103 visitors (0 registered, 103 guests [including 3 identified bots]).
Forum time: 07:27 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5